289 related articles for article (PubMed ID: 15068828)
1. Safety of 5-hydroxy-L-tryptophan.
Das YT; Bagchi M; Bagchi D; Preuss HG
Toxicol Lett; 2004 Apr; 150(1):111-22. PubMed ID: 15068828
[TBL] [Abstract][Full Text] [Related]
2. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M
J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
[TBL] [Abstract][Full Text] [Related]
4. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
[No Abstract] [Full Text] [Related]
5. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.
Turner EH; Loftis JM; Blackwell AD
Pharmacol Ther; 2006 Mar; 109(3):325-38. PubMed ID: 16023217
[TBL] [Abstract][Full Text] [Related]
6. Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.
Love LA; Rader JI; Crofford LJ; Raybourne RB; Principato MA; Page SW; Trucksess MW; Smith MJ; Dugan EM; Turner ML
J Clin Invest; 1993 Mar; 91(3):804-11. PubMed ID: 8450062
[TBL] [Abstract][Full Text] [Related]
7. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.
Crofford LJ; Rader JI; Dalakas MC; Hill RH; Page SW; Needham LL; Brady LS; Heyes MP; Wilder RL; Gold PW
J Clin Invest; 1990 Nov; 86(5):1757-63. PubMed ID: 2243145
[TBL] [Abstract][Full Text] [Related]
8. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms.
Brenneman DE; Page SW; Schultzberg M; Thomas FS; Zelazowski P; Burnet P; Avidor R; Sternberg EM
J Pharmacol Exp Ther; 1993 Aug; 266(2):1029-35. PubMed ID: 8355179
[TBL] [Abstract][Full Text] [Related]
9. Review of L-tryptophan and eosinophilia-myalgia syndrome.
Roufs JB
J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S
Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan.
Klarskov K; Johnson KL; Benson LM; Cragun JD; Gleich GJ; Wrona M; Jiang XR; Dryhurst G; Naylor S
J Rheumatol; 2003 Jan; 30(1):89-95. PubMed ID: 12508395
[TBL] [Abstract][Full Text] [Related]
12. The lessons of eosinophilia-myalgia syndrome.
Duffy J
Hosp Pract (Off Ed); 1992 Apr; 27(4A):65-9, 73-80, 83-90. PubMed ID: 1560091
[No Abstract] [Full Text] [Related]
13. Serotonin precursors in the treatment of depression.
van Praag HM
Adv Biochem Psychopharmacol; 1982; 34():259-86. PubMed ID: 6753514
[TBL] [Abstract][Full Text] [Related]
14. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
[TBL] [Abstract][Full Text] [Related]
15. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
Müller B; Pacholski C; Simat T; Steinhart H
Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
[TBL] [Abstract][Full Text] [Related]
17. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.
Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S
Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085
[TBL] [Abstract][Full Text] [Related]
18. 5-Hydroxytryptophan: a clinically-effective serotonin precursor.
Birdsall TC
Altern Med Rev; 1998 Aug; 3(4):271-80. PubMed ID: 9727088
[TBL] [Abstract][Full Text] [Related]
19. Does 5-hydroxytryptophan cause acute and chronic toxic perturbations in rats?
Preuss HG; Echard B; Talpur N; Funk KA; Bagchi D
Toxicol Mech Methods; 2006; 16(5):281-6. PubMed ID: 20021026
[TBL] [Abstract][Full Text] [Related]
20. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.
Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S
Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
